ArticleBMJ open2025

Efficacy and safety of adjuvant short-course immune checkpoint inhibitors following TACE combined with MWA in patients with BCLC A-B hepatocellular carcinoma: a single-arm, prospective, phase II study protocol.

Yang Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.